Moyamoya disease

Czech version

Authors: V. Přibáň ¹; J. Dostál ¹ ; J. Mraček ¹; J. Baxa ²; P. Duras ²
Authors‘ workplace: Neurochirurgická klinika, LF UK a FN Plzeň ¹; Klinika zobrazovacích metod, LF UK a FN Plzeň ²
Published in: Cesk Slov Neurol N 2021; 84/117(2): 116-125
Category: Minimonography
doi: https://doi.org/10.48095/cccsnn2021116

Overview

Moyamoya disease is bilateral progressive steno-occlusive impairment of the distal internal carotid artery accompanied by the formation of basal collaterals and finally by the exclusive collateralization from the territory of the external carotid artery. Suzuki angiographic classification describes progression of moyamoya disease. Aetiology is not known, but it is probably a combination of inherited and autoimmune factors. Asian population is mostly affected. Ischemic symptoms are typical in a pediatric population, and in adults, haemorrhage is a frequent symptom. Prognosis is poor. Therapy is exclusively surgical, either direct extra-intracranial bypass or indirect revascularization. Indirect techniques utilize potential of neoangiogenesis of vascularized tissue in the proximity of the brain. Combination of direct and indirect revascularization represents optimal treatment of symptomatic patients.

Keywords:

moyamoya disease – Etiology – revascularization techniques – extra-intracranial bypass

Sources

1. Suzuki J, Takaku A. Cerebrovascular „moyamoya“ disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20(3): 288–299. doi: 10.1001/ archneur.1969.00480090076012.

2. Research Committee on Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Intractable Diesases: Guidelines for diagnosis and tratment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 2012; 52(5): 245–266. doi: 10.2176/ nmc.52.245.

3. Takeuchi K, Shimizu K. Hypoplasia of the bilateral internal carotid arteries. Brain Nerve 1957; 9: 37–43.

4. Pool JL, Wood EH, Maki Y. On the cases with abnormal vascular network in the cerebral basal region in the United States. Neurol Med Chir 1966; 8: 255–258.

5. Simon J, Sabouraud O, Guy G et al. Un cas de maladie de Nishimoto. A propos d’une maladie rare et bilaterale de la carotide interne. Rev Neurol 1968; 119(4): 376–383.

6. Busch HF. Unusual collateral circulation in a child with cerebral arterial occlusion. Psychiat Neurol Neurochir 1969; 72(1): 23–28.

7. Taveras JM. Multiple progressive intracranial arterial occlusion: a syndrome of children and young adults. Am J Roentgenol Radium Ther Nucl Med 1969; 106(2): 235–268. doi: 10.2214/ ajr.106.2.viii.

8. Suzuki J. Cerebral angiography. In: Suzuki J (ed). Moyamoya disease. Berlin, Heidelberg, New York, Tokio: Springer-verlag 1986: 17–52.

9. Suzuki J. Etiology. In: Suzuki J (ed). Moyamoya disease. Berlin, Heidelberg, New York, Tokio: Springer-verlag 1986: 131–143.

10. Karasawa J, Kikuchi H, Furuse S et al. Treatment of moyamoya disease with STA-MCA anastomosis. J Neurosurg 1978; 49(5): 679–688. doi: 10.3171/ jns.1978.49.5.0679.

11. Karasawa J, Kikuchi H, Furuse S et al. A surgical treatment of moymamoya disease „encephalo-myo-synangiosis“. Neurol Med Chir (Tokyo) 1977; 17 (1 Pt 1): 29–37. doi: 10.2176/ nmc.17pt1.29.

12. Matsushima Y, Fukai N, Tanaka K et al. A new surgical treatment of moyamoya disease in children: a preliminary report. Surg Neurol 1981; 15(4): 313–320. doi: 10.1016/ s0090-3019(81)80017-1.

13.Kinugasa K, Mandai S, Kamata I et al. Surgical treatment of moyamoya disease: operative technique for encephalo-duro-arterio-myo-synangiosis, its follow-up, clinical results, and angiograms. Neurosurgery 1993; 32(4): 527–531. doi: 10.1227/ 00006123-199304000-00006.

14. Urbánek K, Fárková H, Klaus E. Nishimoto-Takeuchi-Kudo disease: case report. J Neurol Neurosurg Psychiat 1970; 33(5): 671–673. doi: 10.1136/ jnnp.33.5.671.

15. Mraček Z, Kohoutek V. Syndrom moyamoya. Cas Lek Cesk 1974; 113(50–51): 1561–1564.

16. Beneš V st. Syndrom moyamoya. Cesk Pediatr 1982; 37: 674.

17. Kucharík M, Roth J, Faltýnová E et al. Průběh onemocnění moyamoya u pacientky sledované od 3 let do 40 let věku. Neurol praxi 2008; 9(1): 49–51.

18. Häckel M, Beneš V ml. Onemocnění moyamoya. Přehled a soubor 9 nemocných. Cesk Slov Neurol N 1997; 60/ 93(2): 142–151.

19. Yamaguchi T, Tashiro M, Minematsu K et al. Summary of Japanese survey of occlusion of the circle of Willis. In Reports by the research committee on spontaneous occlusion of the circle of Willis. Tokyo: Japanese ministry of Health and welfare 1955: 13–22.

20. Ikezaki K, Inamura T, Kawano T et al. Clinical features of probable Moyamoya disease in Japan. Clin Neurol Neurosurg 1997; 99 (Suppl 2): S173–S177. doi: 10.1016/ s0303-8467(97)00053-x.

21. Baba T, Houkin K, Kuroda S. Novel epidemiological features of Moyamoya disease. J Neurol Neurosurg Psychiatry 2008; 79(8): 900–904. doi: 10.1136/ jnnp.2007.130666.

22. Shuo H, Zhen NG, Mingchao S et al. Etiology and pathogenesis of Moyamoya disease: an update on disease prevalence. Int J Stroke 2017; 12(3): 246–253. doi: 10.1177/ 1747493017694393.

23. Kamada F, Aoki Y, Narisawa A et al. A genome-wide association study identifies RNF 213 as the first Moyamoya disease gene. J Hum Genet 2011; 56(1): 34–40. doi: 10.1038/ jhg.2010.132.

24. Kobayashi H, Brozman M, Kyselová K et al. RNF213 Rare variants in Slovakian and Czech moyamoya disease patients. PLoS ONE 2016; 11(10): e0164759. doi: 10.1371/ journal.pone.0164759.

25. Lee MJ, Falllen S, Zhou Y et al. The impact of moyamoya disease on RNF 213 mutations on the spectrum of plasma protein and microRNA. J Clin Med 2019; 8(10): 1648–1667. doi: 10.3390/ jcm8101648.

26. Zhang H, Rao M, Zhang S. An experimental study on the etiology and pathogenesis of Moyamoya disease. Chin J Neurol 1996; 29: 178–181.

27. Fujimura M, Tominaga T. Diagnosis of moyamoya disease: international standard and regional differences. Neurol Med Chir (Tokyo) 2015; 55(3): 189–193. doi: 10.2176/ nmc.ra.2014-0307.

28. Czabanka M, Peňa-Tapia P, Schubert GA et al. Proposal for a new grading of moyamoya disease in adult patients. Cerebrovasc Dis 2011; 32(1): 41–50. doi: 10.1159/ 000326077.

29.Acker G, Fekonja L, Vajkoczy P. Surgical management of moyamoya disease. Stroke 2018; 49(2): 476–482. doi: 10.1161/ STROKEAHA.117.018563.

30. Funaki T, Takahashi JC, Houkin K et al. Effect of chorioidal collaterall vessels on de novo hemorrhage in moyamoya disease: analysis of nonhemorrhagic hemisferes in the Japan Adult Moyamoya Trial. J Neurosurg 2020; 132(2): 408–414. doi: 10.3171/ 2018.10.JNS181139.

31. Lehman VT, Cogswell PM, Rinaldo L et al. Contemporary and emerging magnetic resonance imaging nethods for evaluation of moyamoya disease. Neurosurg Focus 2019; 47(6): E6. doi: 10.3171/ 2019.9.FOCUS19616.

32. Kuroda S. AMORE Study Group. Asymptomatic moyamoya disease. Literature review and ongoing AMORE study. Neurol Med Chir (Tokyo) 2015; 55(3): 194–198. doi: 10.2176/ nmc.ra.2014-0305.

33. Choi JU, Kim DS, Kim EY et al. Natural history of moyamoya disease: comparison of aktivity of daily living in surgery and non surgery group. Clin Neurol Neurosurg 1997; 99 (2 suppl): S11–S18.

34. Yamada S, Oki K, Itoh I et al. Research Committee on Spontaneous Occlusion fo Circle of Willis (Moyamoya Disease). Effect of surgery and antiplatelet therapy in ten-year follow-up from registry study of research committee on moyamoya disease in Japan. J Stroke Cerebrovasc Dis 2016; 25(2): 340–349. doi: 10.1016/ j.jstrokecerebrovasdis.2015.10.003.

35. Karasawa J, Kikuchi H, Kavamura J et al. Intracranial tranplantation of the omentum for cerebrovascular moyamoya disease: a two-year follow-up study. Surg Neurol 1980; 14(6) 444–449.

36. Kawaguchi T, Fujita S, Hosoda K et al. Multiple burr-hole operation for adult moyamoya disease. J Neurosurg 1996; 84(3): 468–474. doi: 10.3171/ jns.1996.84.3.0468.

37. Kuroda S, Houkin K, Ishikawa T et al. Novel bypass surgery for moyamoya disease using pericranial flap: its impact on cerebral hemodynamics and long-term follow-up. Neurosurgery 2010; 66(6): 1093–1101. doi: 10.1227/ 01.NEU.0000369606.00861.91.

38. Riordan CP, Storey A, Cote DJ et al. Results of more than 20 years of follow-up in pediatric patients with moyamoya disease undergoing pial synangiosis. J Neurosurg Ped 2019; 23: 586–592. doi: 10.3171/ 2019.1.PEDS18457.

39. Guzman R, Lee M, Achrol A et al. Clinical outcome after 450 revascularization procedures for moyamoya disease. J Neurosurg 2009; 111(5): 927–935. doi: 10.3171/ 2009.4.JNS081649.

40. Miyamoto S, Yoshimoto T, Hashimoto N et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 2014; 45(5): 1415–1421. doi: 10.1161/ STROKEAHA.113.004386.

41. Acker G, Fekonja L, Vajkoczy P. Surgical management of moyamoya disease. Stroke 2018; 49(2): 476–482. doi: 10.1161/ STROKEAHA.117.018563.

42. Föhre B, König S. Perioperative management and considerations. In: Vajkoczy P (ed). Surgical techniques in moyamoya vasculopathy. New York: Thieme 2020: 2–7.